New Assays and Tools for Predicting Hepatotoxicity 2011
June 8 - 9, 2011
Филадельфия PA , США
IDIOSYNCRATIC DILI: TRANSITIONING
FROM PRE-CLINICAL TO CLINICAL
How Good Are Currently Available Biomarkers for Idiosyncratic DILI, and Which New Biomarkers Should We Look For?
FEATURED PRESENTATION: Genetic Basis of Susceptibility to DILI
PRE-CLINICAL PREDICTIONS OF LIVER INJURY
In vitro Testing Strategies to Predict Hepatotoxicty-High Content Mechanistic Screening, Mitochondrial Toxicity, and Transporter Assessment
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D
Current Toolbox for the Prediction of Hepatotoxicity
Eric Blomme, D.V.M., Ph.D., DACVP, Senior Project Leader, Abbott Laboratories
LIVER MODELS AND BIOMARKERS
The Utility of Emerging Biomarkers of Liver Injury in Pre-Clinical and Clinical Drug Development
Shelli Schomaker, Senior Scientist, Drug Safety R&D, Pfizer, Inc.
DILI-sim: An in silico Approach to Understanding and Predicting Drug-Induced Liver Injury
Brett A. Howell, Ph.D., Postdoctoral Fellow, The Hamner-UNC Institute for Drug Safety Sciences
MECHANISMS UNDERLYING HEPATOTOXICITY
Prediction of Immune-Mediated Drug-Induced Liver Injury in Pre-Clinical Drug Development
Tsuyoshi Yokoi, Ph.D., Professor, Drug Metabolism and Toxicology, Kanazawa University
FROM PRE-CLINICAL TO CLINICAL
How Good Are Currently Available Biomarkers for Idiosyncratic DILI, and Which New Biomarkers Should We Look For?
FEATURED PRESENTATION: Genetic Basis of Susceptibility to DILI
PRE-CLINICAL PREDICTIONS OF LIVER INJURY
In vitro Testing Strategies to Predict Hepatotoxicty-High Content Mechanistic Screening, Mitochondrial Toxicity, and Transporter Assessment
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D
Current Toolbox for the Prediction of Hepatotoxicity
Eric Blomme, D.V.M., Ph.D., DACVP, Senior Project Leader, Abbott Laboratories
LIVER MODELS AND BIOMARKERS
The Utility of Emerging Biomarkers of Liver Injury in Pre-Clinical and Clinical Drug Development
Shelli Schomaker, Senior Scientist, Drug Safety R&D, Pfizer, Inc.
DILI-sim: An in silico Approach to Understanding and Predicting Drug-Induced Liver Injury
Brett A. Howell, Ph.D., Postdoctoral Fellow, The Hamner-UNC Institute for Drug Safety Sciences
MECHANISMS UNDERLYING HEPATOTOXICITY
Prediction of Immune-Mediated Drug-Induced Liver Injury in Pre-Clinical Drug Development
Tsuyoshi Yokoi, Ph.D., Professor, Drug Metabolism and Toxicology, Kanazawa University
Место проведения
Location: Sheraton Philadelphia City Center Hotel
Обратная связь
17th & Race St. Philadelphia , USA
Похожие мероприятия
New Assays and Tools for Predicting Hepatotoxicity June 8 - 9, 2011
